AR036028A1 - Compuesto de pirimidina, procedimiento para su preparacion, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos en la preparacion de las composiciones mencionadas - Google Patents
Compuesto de pirimidina, procedimiento para su preparacion, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos en la preparacion de las composiciones mencionadasInfo
- Publication number
- AR036028A1 AR036028A1 ARP020101915A ARP020101915A AR036028A1 AR 036028 A1 AR036028 A1 AR 036028A1 AR P020101915 A ARP020101915 A AR P020101915A AR P020101915 A ARP020101915 A AR P020101915A AR 036028 A1 AR036028 A1 AR 036028A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compound
- formula
- group
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000036407 pain Effects 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de pirimidina de fórmula (1) en la que: R1 se selecciona del grupo constituido por H, alquilo C1-6, alquilo C1-2 sustituido con 1 a 5 átomos de flúor, alquenilo C3-6, alquinilo C3-6, cicloalquil C3-10-alquilo C0-6, cicloalquilo puente C4-12, A(CR4R5)n y B(CR4R5)n; R2 es alquilo C1-2 sustituido con 1 a 5 átomos de flúor; R3 se selecciona del grupo constituido por alquilo C1-6, NH2 y R7CONH; R4 y R5 se seleccionan independientemente entre H o alquilo C1-6; A es un heteroarilo insustituido de 5 o 6 miembros o un arilo insustituido de 6 miembros, o un heteroarilo de 5 o 6 miembros o un arilo de 6 miembros sustituidos con uno o más R6; R6 se selecciona del grupo constituido por halógeno, alquilo C1-6, alquilo C1-6 sustituido con uno o más átomos de flúor, alcoxi C1-6, alcoxi C1-6 sustituido con uno o más F, NH2SO2 y alquil C1-6-SO2; B se selecciona del grupo constituido por el grupo de fórmulas (2), donde: ) define el punto de unión del anillo; R7 se selecciona del grupo constituido por H, alquilo C1-6, alcoxi C1-6, alquil C1-6-O-alquilo C1-6, fenilo, HO2C-alquilo C1-6, alquil C1-6-OCO-alquilo C1-6, alquil C1-6-OCO, H2N-alquilo C1-6, alquil C1-6-OCONH-alquilo C1-6 y alquil C1-6-CONH-alquilo C1-6; y n es 0 a 4. Dichos compuestos son de aplicación en medicina veterinaria, en función de su selectiva actividad inhibidora de las enzimas COX-2, particularmente en el tratamiento de dolores - agudos - crónicos - estados febriles e inflamatorios mediados por dichas enzimas, inclusive dolores menopáusicos. Se describen además los objetos restantes, invocados en el título, inclusive un procedimiento para la preparación de dichos compuestos caracterizado porque comprende: A) hacer reaccionar un alcohol R1OH o una de sus derivados protegidos con un compuesto de la fórmula (3), y después, y si fuera necesario, (B), interconvertir un compuesto de la fórmula (1) en otro compuesto de la fórmula (1); y/o (C), desproteger un derivado protegido de un compuesto de la fórmula (1). Una composición farmacéutica que comprende un compuesto de la fórmula (1) en mezcla con uno o más vehículos o excipientes fisiológicamente aceptables. Uso de un compuesto de la fórmula (1) para preparar un agente terapéutico para el tratamiento de un trastorno que está mediado por la COX-2, por ejemplo, un trastorno inflamatorio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0112802.4A GB0112802D0 (en) | 2001-05-25 | 2001-05-25 | Pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036028A1 true AR036028A1 (es) | 2004-08-04 |
Family
ID=9915322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101915A AR036028A1 (es) | 2001-05-25 | 2002-05-23 | Compuesto de pirimidina, procedimiento para su preparacion, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos en la preparacion de las composiciones mencionadas |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7026327B2 (es) |
| EP (2) | EP1493735B1 (es) |
| JP (1) | JP4291688B2 (es) |
| KR (1) | KR100889427B1 (es) |
| CN (1) | CN1255387C (es) |
| AR (1) | AR036028A1 (es) |
| AT (2) | ATE325103T1 (es) |
| AU (1) | AU2002302764B2 (es) |
| BR (1) | BR0209787A (es) |
| CA (1) | CA2448192A1 (es) |
| CO (1) | CO5540311A2 (es) |
| CZ (1) | CZ20033204A3 (es) |
| DE (2) | DE60229669D1 (es) |
| DK (1) | DK1390351T3 (es) |
| ES (2) | ES2262809T3 (es) |
| GB (1) | GB0112802D0 (es) |
| HU (1) | HUP0401280A3 (es) |
| IL (1) | IL158799A0 (es) |
| MX (1) | MXPA03010583A (es) |
| MY (1) | MY130750A (es) |
| NO (1) | NO326949B1 (es) |
| NZ (1) | NZ529719A (es) |
| PL (1) | PL366514A1 (es) |
| PT (1) | PT1390351E (es) |
| SI (1) | SI1390351T1 (es) |
| TW (1) | TWI327140B (es) |
| WO (1) | WO2002096885A1 (es) |
| ZA (1) | ZA200308826B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| DE60305053T2 (de) | 2002-08-19 | 2006-08-31 | Glaxo Group Ltd., Greenford | Pyrimidinderivate als selektive cox-2-inhibitoren |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| GB0227443D0 (en) * | 2002-11-25 | 2002-12-31 | Glaxo Group Ltd | Pyrimidine derivatives |
| US20070142411A1 (en) * | 2003-11-19 | 2007-06-21 | James Hagan | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| US20070270428A1 (en) * | 2003-11-19 | 2007-11-22 | James Hagan | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders |
| EP4027993A4 (en) * | 2019-09-13 | 2023-09-20 | The Broad Institute Inc. | CYCLO-OXYGENASE 2 INHIBITORS AND THEIR USES |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3149109A (en) | 1962-02-20 | 1964-09-15 | Searle & Co | Certain 4-trifluoromethyl-2-(oxy/thio) pyrimidines |
| GB1121922A (en) * | 1966-06-17 | 1968-07-31 | Ici Ltd | Pyrimidine derivatives |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| CA2276946A1 (en) | 1993-11-30 | 1995-06-08 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions containing the same |
| US5945426A (en) | 1994-09-09 | 1999-08-31 | Nippon Shinyaku Co., Ltd. | Derivatives of pyrimidine for treating acute cerebrovascular disorders |
| US5596008A (en) | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| US6342510B1 (en) | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
| US6020343A (en) | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| JPH09241161A (ja) | 1996-03-08 | 1997-09-16 | Nippon Shinyaku Co Ltd | 医 薬 |
| JPH09266197A (ja) * | 1996-03-28 | 1997-10-07 | Mitsubishi Electric Corp | 半導体装置およびその製造方法 |
| IL127441A (en) * | 1996-07-18 | 2003-02-12 | Merck Frosst Canada Inc | Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors |
| CN100558356C (zh) | 1996-10-15 | 2009-11-11 | G.D.瑟尔公司 | 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法 |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| EP0994860A1 (en) | 1997-07-03 | 2000-04-26 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| ATE317845T1 (de) * | 1997-09-05 | 2006-03-15 | Glaxo Group Ltd | Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate |
| US5972986A (en) | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| DE19909541A1 (de) | 1998-03-06 | 1999-10-14 | American Cyanamid Co | Herbizide 2-Aryloxy- bzw. 2-Arylthio-6-arylpyrimidine |
| US6306866B1 (en) | 1998-03-06 | 2001-10-23 | American Cyanamid Company | Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents |
| US6313072B1 (en) | 1999-02-18 | 2001-11-06 | American Cyanamid Company | Herbicidal 2-aryloxy-or 2-arylthio-6-arylpyrimidines |
| WO2000052008A1 (en) * | 1999-02-27 | 2000-09-08 | Glaxo Group Limited | Pyrazolopyridines |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| GB9930358D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Process for the preparation of chemical compounds |
| GB0002336D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| GB0002312D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| US6756498B2 (en) * | 2001-04-27 | 2004-06-29 | Smithkline Beecham Corporation | Process for the preparation of chemical compounds |
| GB0112803D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112802D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| US6861249B1 (en) * | 2002-04-09 | 2005-03-01 | David Kent | Microbial spray for animal waste |
-
2001
- 2001-05-25 GB GBGB0112802.4A patent/GB0112802D0/en not_active Ceased
-
2002
- 2002-05-23 PT PT02730443T patent/PT1390351E/pt unknown
- 2002-05-23 JP JP2003500064A patent/JP4291688B2/ja not_active Expired - Fee Related
- 2002-05-23 PL PL02366514A patent/PL366514A1/xx not_active Application Discontinuation
- 2002-05-23 ES ES02730443T patent/ES2262809T3/es not_active Expired - Lifetime
- 2002-05-23 CN CNB028106377A patent/CN1255387C/zh not_active Expired - Fee Related
- 2002-05-23 HU HU0401280A patent/HUP0401280A3/hu unknown
- 2002-05-23 IL IL15879902A patent/IL158799A0/xx not_active IP Right Cessation
- 2002-05-23 NZ NZ529719A patent/NZ529719A/en unknown
- 2002-05-23 ES ES04077503T patent/ES2316918T3/es not_active Expired - Lifetime
- 2002-05-23 US US10/477,547 patent/US7026327B2/en not_active Expired - Fee Related
- 2002-05-23 MX MXPA03010583A patent/MXPA03010583A/es active IP Right Grant
- 2002-05-23 CA CA002448192A patent/CA2448192A1/en not_active Abandoned
- 2002-05-23 EP EP04077503A patent/EP1493735B1/en not_active Expired - Lifetime
- 2002-05-23 AR ARP020101915A patent/AR036028A1/es unknown
- 2002-05-23 EP EP02730443A patent/EP1390351B1/en not_active Expired - Lifetime
- 2002-05-23 DE DE60229669T patent/DE60229669D1/de not_active Expired - Lifetime
- 2002-05-23 AT AT02730443T patent/ATE325103T1/de active
- 2002-05-23 CZ CZ20033204A patent/CZ20033204A3/cs unknown
- 2002-05-23 BR BR0209787-7A patent/BR0209787A/pt not_active Application Discontinuation
- 2002-05-23 MY MYPI20021911A patent/MY130750A/en unknown
- 2002-05-23 DK DK02730443T patent/DK1390351T3/da active
- 2002-05-23 AT AT04077503T patent/ATE412637T1/de not_active IP Right Cessation
- 2002-05-23 KR KR1020037015401A patent/KR100889427B1/ko not_active Expired - Fee Related
- 2002-05-23 DE DE60211149T patent/DE60211149T2/de not_active Expired - Lifetime
- 2002-05-23 SI SI200230349T patent/SI1390351T1/sl unknown
- 2002-05-23 WO PCT/GB2002/002415 patent/WO2002096885A1/en not_active Ceased
- 2002-05-23 TW TW091110837A patent/TWI327140B/zh not_active IP Right Cessation
- 2002-05-23 AU AU2002302764A patent/AU2002302764B2/en not_active Ceased
-
2003
- 2003-11-12 ZA ZA200308826A patent/ZA200308826B/en unknown
- 2003-11-24 NO NO20035206A patent/NO326949B1/no not_active IP Right Cessation
- 2003-11-25 CO CO03103980A patent/CO5540311A2/es not_active Application Discontinuation
-
2005
- 2005-04-20 US US11/110,118 patent/US20050187235A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013542A1 (es) | Compuesto 5-azaquinoxalinico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farma | |
| AR038818A1 (es) | Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| FI921030A0 (fi) | Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning. | |
| BR9914379A (pt) | Composto, processo para a preparação de um composto, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| BR9910971A (pt) | Composto, processos para a preparação de um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| PE131699A1 (es) | Inhibidores de aminotiazol de cinasas dependientes de ciclina | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| MEP24608A (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| MX9303145A (es) | 7-(2-aminoetil)benzotiazolonas. | |
| AR036028A1 (es) | Compuesto de pirimidina, procedimiento para su preparacion, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos en la preparacion de las composiciones mencionadas | |
| NO20044041L (no) | Okso-azabisykliske forbindelser | |
| DK317382A (da) | Fremgangsmaade til fremstilling af pyrrolidinderivater | |
| ES2063309T3 (es) | Derivados de pirimidina 3-oxido halogenados, su utilizacion para el tratamiento y la prevencion de la caida de los cabellos y para estimular su crecimiento. | |
| BR9102322A (pt) | Derivados de morfolino-ureia,processo para sua preparacao,composicoes inseticidas e acaricidas,processo para o combate de insetos e acaros,utilizacao e processo para a preparacao de composicoes | |
| AR030540A1 (es) | Compuestos antipicornavirales y composiciones, su uso farmaceutico, y materiales para su sintesis | |
| DE69317439D1 (de) | Azoxycyanbenzol-Derivate | |
| SE9804212D0 (sv) | Compounds | |
| DE60214401D1 (de) | Hetero-bicyclische crf antagonisten | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| AR035110A1 (es) | Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| DK0652874T3 (da) | 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler | |
| EA200400690A1 (ru) | Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |